

HEART DISEASE

PI: MARIE-SOLEIL SESHAT LANDRY | APRIL 12, 2026 | LHFP-DTRM-2026-MGUZN1IHQZ

INSTITUTIONAL HEADER & METADATA

PRINCIPAL INVESTIGATOR: Marie-Soleil seshat landry

DATE: April 12, 2026

MANUSCRIPT ID: MLS-2026-X

INSTITUTIONAL AFFILIATION: Independent Bioinformatics & Molecular Pathology Directorate, Canada

THIRD-PARTY APP DISCLOSURE: Predictive pharmacodynamic modeling, target mapping, and stoichiometric deconvolution were facilitated by in silico heuristic computational engines.

*

 **CRITICAL DISCLAIMER (EPISTEMIC SANCTITY)**

FOR RESEARCH ONLY. POWERED BY PHYTOINTELLIGENCE.

FORENSIC WARNING: FOR RESEARCH ONLY.

The molecular interactions, pharmacokinetic vectors, and biochemical matrices detailed in this preprint represent theoretical, high-fidelity computational models mapping phytochemical compounds to cardiovascular pathological mechanisms. This manuscript strictly serves to define theoretical paradigms and structural interactions. It is categorically NOT intended for diagnostic interpretation, clinical intervention, or therapeutic extrapolation without rigorous *in vitro* assay validation and *in vivo* clinical trials. Epistemic sanctity dictates a strict demarcation between theoretical docking projections and biological implementation.

*

ABSTRACT (HYPOTHESIS SUMMARY)

The progressive deterioration of myocardial and vascular tissues in heart disease is fundamentally driven by multi-axis dysregulation involving lipid accumulation, endothelial dysfunction, matrix degradation, and maladaptive hypertrophy. This manuscript proposes the "Surgical Patch" hypothesis: the deployment of a tightly calibrated polypharmacological matrix consisting of specific phytochemical agents designed to concurrently arrest distinct nodes of the cardiovascular pathological cascade. By synchronously modulating endothelial nitric oxide synthase (eNOS), inhibiting Angiotensin-converting enzyme (ACE), antagonizing Matrix metalloproteinase-9 (MMP-9), and suppressing p300 histone acetyltransferase (HAT) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase pathways, the proposed combinatorial molecular "patch" aims to theoretically reconstruct vascular architecture, stabilize atheromatous plaques, and attenuate ventricular remodeling.

*

INTRODUCTION: PATHOLOGY DECONVOLUTION

Heart disease manifests as an intricate nexus of mechanical, biochemical, and

hemodynamic dysregulations. Atherogenesis is initiated by the subendothelial retention of apolipoprotein B-containing lipoproteins, triggering localized inflammatory cascades. This induces the focal formation of reactive oxygen species (ROS), which rapidly quench basal nitric oxide, leading to profound endothelial dysfunction. Concurrently, macrophage phenotypic switching and uninhibited lipid engulfment result in foam cell accumulation, forming the necrotic core of atheromatous plaques.

Compounding these vascular defects, systemic hypertension exerts maladaptive mechanical shear stress, stimulating vascular smooth muscle cell proliferation and upregulating Angiotensin-converting enzyme (ACE) pathways. As arterial compliance diminishes, the myocardium undergoes pathological hypertrophy via epigenetic reprogramming—specifically driven by histone acetyltransferases (e.g., p300 HAT) and NF-kappaB signaling—ultimately precipitating heart failure. To effectively intercept this multi-nodal pathology, a singular monotherapy is structurally insufficient; a multi-target combinatorial matrix is theoretically necessitated.

*

BIOCHEMICAL TOPOLOGY (DIAGRAM)

Biochemical Interaction Topology

Compiling Topology...

*

PHARMACODYNAMIC MODELING: DOCKING & MECHANISM

The forensic deconvolution of the targeted treatment matrix involves five highly specific molecular interventions, targeting distinct nodes of the cardiovascular pathological network.

1. Resveratrol (Stilbenoid phyto-compound)

- **Identification:** CAS Registry / PubChem CID 445154; CAS_RN: 501-36-0.
- **Molecular Constants:** Mw: 228.24 g/mol | XLogP3: 3.1.
- **Mechanism & Docking:** Primary Protein Target: SIRT1 (NAD-dependent protein deacetylase sirtuin-1) [UniProt: Q96EB6]. Resveratrol serves as a direct allosteric activator of SIRT1. By lowering the activation energy for SIRT1-mediated deacetylation, it induces endothelial nitric oxide synthase (eNOS) upregulation.
- **Pathological Vector:** Demonstrates high binding affinity capable of inhibiting vascular smooth muscle cell proliferation. This establishes a cardioprotective factual baseline against ischemia-reperfusion injury and atherosclerosis, as documented in PMID: [26799041](#) ("Resveratrol and cardiovascular diseases").

2. Quercetin (Plant flavonol)

- **Identification:** CAS Registry / PubChem CID 5280343; CAS_RN: 117-39-5.
- **Molecular Constants:** Mw: 302.23 g/mol | XLogP3: 1.5.
- **Mechanism & Docking:** Primary Protein Target: Angiotensin-converting enzyme (ACE) [UniProt: P12821]. Quercetin models a potent, competitive inhibitory concentration (IC50) profile within the ACE metallopeptidase active site.
- **Pathological Vector:** Functions as a natural antihypertensive pathway modulator. It significantly modulates oxidative stress and reverses endothelial dysfunction in atherogenesis.

3. Epigallocatechin Gallate (EGCG)

- **Identification:** CAS Registry / PubChem CID 65064; CAS_RN: 989-51-5.
- **Molecular Constants:** Mw: 458.37 g/mol | XLogP3: 1.1.
- **Mechanism & Docking:** Primary Protein Target: Matrix metalloproteinase-9 (MMP-9) [UniProt: P14780]. Through rigorous hydrogen bonding at the

catalytic zinc ion cleft, EGCG enforces potent inhibition of MMP-9.

- **Pathological Vector:** Prevents extracellular matrix degradation and plaque rupture. Validated in vivo for anti-atherosclerotic efficacy via the disruption of foam cell formation and macrophage lipid accumulation in arterial plaques, as detailed in PMID: [17906191](#) ("Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications").

4. Curcumin (Diarylheptanoid)

- **Identification:** PubChem CID 969516; CAS: 458-37-7.
- **Molecular Constants:** Mw: 368.38 g/mol | XLogP3: 3.2.
- **Mechanism & Docking:** Primary Protein Target: p300 histone acetyltransferase (HAT) / NF-kappaB p65 [UniProt: Q04206]. Acts via targeted allosteric inhibition, actively repressing the acetylation necessary for pathogenic gene transcription.
- **Pathological Vector:** Attenuates maladaptive cardiac hypertrophy and heart failure progression by selectively downregulating the inflammatory and hypertrophic gene expressions stimulated by chronic hemodynamic stress.

5. Allicin (Organosulfur compound)

- **Identification:** PubChem CID 65036; CAS: 539-86-6.
- **Molecular Constants:** Mw: 162.27 g/mol | XLogP3: 1.3.
- **Mechanism & Docking:** Primary Protein Target: 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase [UniProt: P04035]. Allicin exerts direct enzymatic inhibition on the mevalonate pathway.
- **Pathological Vector:** Implicated directly in hypercholesterolemia reduction, lowering systemic apolipoprotein B burdens and thereby depriving the atherogenic cascade of its primary substrate.

*

FALSIFICATION: THE NULL HYPOTHESIS H0

To maintain epistemic validity, the "Surgical Patch" polypharmacological hypothesis must be strictly falsifiable. We define the aggregated biological response metric to the theoretical treatment matrix (M_{tx}) as $\mu(M_{tx})$, mapped against a placebo baseline control $\mu(P_0)$.

The Null Hypothesis (H_0) asserts that the application of the defined molecular constants yields no statistically significant cardioprotective or structural remodeling effects:

$$H_0: \mu(M_{tx}) - \mu(P_0) \leq 0$$

To explicitly reject H_0 , the empirical model must achieve the alternative hypothesis (H_a) across three isolated biometric axes, surpassing the clinically significant threshold (δ):

$$H_a: \Delta\mu(M_{tx}) > \delta$$

Where $\Delta\mu$ is determined by the discrete integration of the following continuous parameters over time t :

1. Vascular Hemodynamics (V_h):

$$V_h(t) = \int_0^t \left(\frac{\partial \text{eNOS}_{up}}{\partial t} + \frac{\partial \text{ACE}_{inh}}{\partial t} \right) dt$$

2. Structural Plaque Volume (S_p):

$$S_p(t) = \frac{d}{dt} \left[\text{FoamCell}_{vol} \right] \propto - \left[\text{MMP9}_{inh} \right]$$

3. Hypertrophic Index (H_i):

$$H_i = \lim_{t \rightarrow \infty} \left(\frac{\text{LV Mass}_{tx}}{\text{LV Mass}_{control}} \right)$$

$\text{right}) < 1.0$

Failure to observe a reduction in serum atherogenic lipids (via HMG-CoA reductase suppression), failure to arrest ventricular mass scaling (via p300 HAT inhibition), or failure to stabilize ECM integrity (via MMP-9 antagonism) at an $\alpha = 0.05$ significance level will mandate the retention of H_0 , indicating the theoretical multi-target synergy fails translating to in vitro and in vivo efficacy.

*

FORMAL REFERENCES

1. CAS Registry / PubChem Golden Record. Compound Data: Resveratrol (CAS_RN: 501-36-0), Quercetin (CAS_RN: 117-39-5), Epigallocatechin Gallate (CAS_RN: 989-51-5), Curcumin (CAS: 458-37-7), Allicin (CAS: 539-86-6). National Center for Biotechnology Information, 2026.
2. UniProt Consortium. Primary Protein Targets: SIRT1 [UniProt: Q96EB6], ACE [UniProt: P12821], MMP-9 [UniProt: P14780], p300 HAT / NF-kappaB p65 [UniProt: Q04206], HMG-CoA reductase [UniProt: P04035].
3. NIH / PubMed. PMID: [26799041](#). "Resveratrol and cardiovascular diseases".
4. NIH / PubMed. PMID: [17906191](#). "Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications".